Dutch biotech SME behind PreCursor-M, a methylation-based molecular test for cervical precancer and cancer detection, now embedded in European risk-based screening research.
Self-Screen is a Dutch biotech SME that develops molecular diagnostic tests for cervical cancer screening. Their lead product, PreCursor-M, is a methylation-based assay designed to detect cervical precancer and cancer with higher specificity than traditional cytology or HPV triage. They combine laboratory development with clinical validation studies, and more recently contribute to research on risk-based screening strategies that integrate biomarkers, predictive models, and health-economic analysis.
VALID-SCREEN (SME-2, coordinator) was dedicated to validating PreCursor-M for cervical (pre)cancer detection; RISCC continues applying their assay within risk-based screening research.
VALID-SCREEN was a €3.26M SME-2 validation project with the company as coordinator, explicitly focused on evidence generation for regulatory and clinical adoption.
RISCC (2020–2024) is a RIA consortium on risk-based screening listing risk stratification and predictive modelling as core keywords.
RISCC keywords explicitly include predictive modelling and health-economic modelling as consortium themes to which Self-Screen contributes.
RISCC lists digital applications among its topics, reflecting the company's move toward screening workflows that integrate software tools.
In 2015–2019 the company was focused on one thing: getting its own product, PreCursor-M, through clinical validation under a large SME-2 grant where it acted as coordinator. From 2020 onward it shifted into a partner role in the RISCC consortium, where the agenda broadens beyond a single assay to risk stratification, predictive models, health-economic evaluation, and digital screening tools. The trajectory is a classic SME path: prove the product, then plug into a wider research network that positions it inside future screening guidelines.
They are moving from standalone product validation into consortium-level work on integrated, risk-based screening — a useful partner for anyone building projects that combine molecular diagnostics with modelling and digital tools.
Self-Screen has shown it can both lead and follow: it coordinated a multi-million SME-2 validation project and then joined a larger RIA consortium as a specialist partner. Across both projects it has worked with ten partners in nine countries, suggesting a focused European network rather than a sprawling one. They appear to be the type of SME that brings a concrete technology asset to a consortium rather than a broad research capacity.
A compact European network of 10 partners across 9 countries, with no single country dominating beyond the Netherlands as home base. The network profile fits a product-focused SME that picks partners for clinical reach and complementary expertise rather than volume.
Very few SMEs actually coordinate a €3.26M SME-2 project, and fewer still have a proprietary methylation assay for cervical (pre)cancer with EU-funded clinical validation behind it. That combination — a commercial product plus independent evidence plus a seat inside Europe's leading cervical screening research consortium — is what makes them stand out from generic diagnostics companies and from purely academic cervical-screening groups.
